Navigation Links
PharmAthene to Present at the 24th Annual ROTH Conference on Monday, March 12, 2012
Date:3/5/2012

ANNAPOLIS, Md., March 5, 2012 /PRNewswire/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that management will present at the ROTH 24th Annual OC Growth Stock Conference on Monday, March 12, 2012 at 5:30 pm PT at the Ritz-Carlton Laguna Niguel in Dana Point, CA. Event:

24th Annual ROTH ConferenceDate:

Monday, March 12, 2012 at 5:30 pm Place:

Ritz-Carlton Laguna Niguel, Salon 1Time:

5:30 pm PTAbout PharmAthene, Inc.PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:

  • SparVax™ - a second generation recombinant protective antigen (rPA) anthrax vaccine
  • Valortim® - a fully human monoclonal antibody for the prevention and treatment of anthrax infection
  • Recombinant BChE - a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents
  • In addition, pursuant to an opinion issued September 22, 2011 from the Delaware Court of Chancery, PharmAthene is entitled to 50% of the profits over 10 years from all sales of SIGA Technologies' ST-246, and related products, a novel smallpox antiviral agent being developed by SIGA for the treatment and prevention of morbidity and mortality associated with exposure to the causative agent of smallpox (once SIGA receives the first $40 million in net profits from sales of ST-246.) For more information about PharmAthene, please visit www.PharmAthene.com.


    '/>"/>
    SOURCE PharmAthene, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1

    Related biology technology :

    1. PharmAthene to Present at the Noble Financial Eighth Annual Equity Conference on Tuesday, January 17, 2012
    2. PharmAthene Reports Third Quarter 2011 Financial and Operating Results
    3. PharmAthene Progresses Second Generation rPA Anthrax Vaccine
    4. PharmAthene Appoints Brian A. Markison to the Companys Board of Directors
    5. PharmAthene Achieves Significant Progress in SparVax™ Anthrax Vaccine Program
    6. Department of Defense Awards $5.7 Million Contract to PharmAthene for Nerve Agent Medical Countermeasure Program
    7. PharmAthene Selected for Inclusion in the Russell Global Index and Russell 3000 Index
    8. PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer
    9. PharmAthene Completes $6.5 Million Registered Direct Offering
    10. PharmAthene Reports First Quarter 2011 Financial and Operating Results
    11. PharmAthene to Host Year-End 2010 Earnings Conference Call and Webcast on Monday, March 28, 2011
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
    (Date:6/23/2016)... -- The Prostate Cancer Foundation (PCF) is pleased to announce 24 new ... prostate cancer. Members of the Class of 2016 were selected from a pool ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
    (Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking ... Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. ... Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our capacity as ...
    (Date:6/23/2016)... -- Andrew D Zelenetz , ... Published recently in Oncology & ... Andrew D Zelenetz , discusses the fact ... placing an increasing burden on healthcare systems worldwide, ... the patents on many biologics expiring, interest in ...
    Breaking Biology Technology:
    (Date:6/16/2016)... , June 16, 2016 ... size is expected to reach USD 1.83 billion ... Grand View Research, Inc. Technological proliferation and increasing ... applications are expected to drive the market growth. ... , The development of advanced multimodal ...
    (Date:6/7/2016)... 2016  Syngrafii Inc. and San Antonio Credit ... includes integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution ... will result in greater convenience for SACU members ... maintaining existing document workflow and compliance requirements. ... Highlights: ...
    (Date:6/2/2016)... 2, 2016 Perimeter Surveillance & ... Systems, Physical Infrastructure, Support & Other Service  ... offers comprehensive analysis of the global Border ... generate revenues of $17.98 billion in 2016. ... a leader in software and hardware technologies for advanced ...
    Breaking Biology News(10 mins):